

*The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.*

**Rifampin for Injection, USP, 600mg/vial**

**Recall initiated by Distributor: Mylan Institutional LLC**

**Product Manufacturer: Sterisience Specialties Private Limited - Sterile Product Division**

| <b>NDC#</b>  | <b>Material Description/ Strength</b>    | <b>Size</b> | <b>Lot No</b> | <b>Expiry</b> |
|--------------|--|-------------|---------------|---------------|
| 67457-445-60 | Rifampin for Injection, USP, 600mg/vial  | 20mL Vial   | 7008990       | Dec-2022      |
| 67457-445-60 | Rifampin for Injection, USP, 600mg/vial  | 20mL Vial   | 7009025       | Feb-2023      |
| 67457-445-60 | Rifampin for Injection , USP, 600mg/vial | 20mL Vial   | 7009085       | Apr-2023      |
| 67457-445-60 | Rifampin for Injection, USP, 600mg/vial  | 20mL Vial   | 7009086       | Aor-2023      |

Mylan Institutional LLC (a Viatrix company) is conducting a recall at the **retail** level of four (4) batches of Rifampin for Injection, USP, 600 mg/vial packaged in a 20mL glass vial. These batches are being recalled due to related compound results obtained during routine stability testing that were found out of specification. These batches were distributed in the US between June 4, 2020, and February 21, 2022. To date, Viatrix has not received any adverse events for the subject product lots.